^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TG01 vaccine

    i
    Other names: TG01 vaccine
    Associations

    News

    Trials
    Company:
    Circio Holding, IOVaxis
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    TESLA: Tg01 Vaccine / Qs-21 Stimulonâ„¢ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P2; Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RAS mutation
    |
    Signatera™
    |
    balstilimab (AGEN2034) • TG01 vaccine
    1year
    The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Capoxigem (apricoxib) • TG01 vaccine
    over1year
    The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Oslo University Hospital
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Capoxigem (apricoxib) • TG01 vaccine
    over1year
    Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA). (ASCO 2023)
    Br J Cancer 2020 122:971-77. Clinical trial information: NCT05638698.
    P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Minimal residual disease
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    RAS mutation
    |
    Signatera™
    |
    balstilimab (AGEN2034) • TG01 vaccine
    almost2years
    TESLA: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting
    Enrollment open
    |
    RAS mutation
    |
    Signatera™
    |
    balstilimab (AGEN2034) • TG01 vaccine
    almost2years
    TESLA: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P2; N=24; Not yet recruiting; Sponsor:University of Kansas Medical Center
    New P2 trial
    |
    RAS mutation
    |
    Signatera™
    |
    balstilimab (AGEN2034) • TG01 vaccine